Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its price objective lowered by equities research analysts at Morgan Stanley from $5.90 to $5.60 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley‘s target price indicates a potential upside of 105.88% from the company’s previous close.
RXRX has been the subject of a number of other reports. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Monday, October 19th. Wall Street Zen raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. cut their price objective on Recursion Pharmaceuticals from $10.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.52.
View Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Down 3.9%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). The business had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same quarter last year, the business posted ($0.36) EPS. Research analysts expect that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. This represents a 13.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the transaction, the director owned 6,068,287 shares of the company’s stock, valued at approximately $23,544,953.56. This trade represents a 0.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 167,408 shares of company stock worth $701,276 over the last ninety days. Company insiders own 6.65% of the company’s stock.
Institutional Trading of Recursion Pharmaceuticals
A number of institutional investors have recently modified their holdings of RXRX. Renaissance Technologies LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth about $7,370,000. Jump Financial LLC boosted its position in Recursion Pharmaceuticals by 145.0% during the third quarter. Jump Financial LLC now owns 2,497,200 shares of the company’s stock valued at $10,313,000 after purchasing an additional 1,478,027 shares during the last quarter. First Trust Advisors LP boosted its position in Recursion Pharmaceuticals by 16.8% during the third quarter. First Trust Advisors LP now owns 3,551,885 shares of the company’s stock valued at $14,669,000 after purchasing an additional 510,056 shares during the last quarter. Bank of America Corp DE boosted its position in Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after purchasing an additional 331,048 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.
Trending Headlines about Recursion Pharmaceuticals
These are some of the RXRX headlines that stood out recently:
- Positive Sentiment: Recursion said it aligned with the FDA on the registrational Phase 3 trial design for REC-4881, its experimental treatment for familial adenomatous polyposis (FAP). The agreement advances the program toward a late-stage trial and reduces uncertainty about the study design. Recursion announces FDA alignment on REC-4881 Phase 3 design
- Neutral Sentiment: The development also showcases a drug candidate identified through Recursion’s AI-based discovery platform. However, REC-4881 is not yet proven in Phase 3, and FAP represents a relatively small treatment opportunity; investors are looking for further details and clinical evidence. Why Recursion Pharmaceuticals stock is up today
- Negative Sentiment: Analyst actions added pressure: Morgan Stanley cut its price target to $5.60 from $5.90 while maintaining an Equal Weight rating, and JPMorgan also lowered its target. A separate report linked a downgrade to RXRX reaching a new 52-week low, signaling continued caution despite the clinical news. Recursion reaches new 52-week low following analyst downgrade Morgan Stanley price target update
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Further Reading
- Five stocks we like better than Recursion Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
